An observational study in Differentiated Thyroid Carcinoma, Papillary Thyroid Carcinoma and Follicular Thyroid Carcinoma, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Assiut University · Observational
This observational study aims to evaluate the relationship between preoperative Bethesda classification of fine-needle aspiration cytology and postoperative American Thyroid Association (ATA) risk stratification in patients with differentiated thyroid carcinoma.
Differentiated thyroid carcinoma (DTC) accounts for the majority of thyroid cancers and generally has a favorable prognosis. The incidence of DTC has increased worldwide, largely due to improved detection of thyroid nodules with high-resolution ultrasonography and the widespread use of fine-needle aspiration cytology (FNAC).
The Bethesda System for Reporting Thyroid Cytopathology classifies thyroid cytology into six diagnostic categories, each associated with a specific risk of malignancy and recommended clinical management. While the Bethesda classification is useful for predicting the likelihood of malignancy, its relationship with postoperative prognosis and risk stratification remains less clear.
After thyroidectomy, patients are stratified according to the American Thyroid Association (ATA) risk stratification system into low-, intermediate-, and high-risk categories. Understanding the association between the preoperative Bethesda category and postoperative ATA risk stratification may improve early prognostic assessment and help optimize treatment and follow-up strategies.
This observational study will examine the relationship between preoperative Bethesda classification and postoperative ATA risk stratification in patients with histopathologically confirmed differentiated thyroid carcinoma.
175 studies on the registry are indexed under Thyroid Cancer, Papillary; 52 are open to participants now.
This study's planned enrollment of 100 is below the median of 198 across 66 observational studies indexed under Thyroid Cancer, Papillary.
Browse Thyroid Cancer, Papillary studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with histopathologically confirmed differentiated thyroid carcinoma who underwent preoperative fine-needle aspiration cytology and are followed at the Nuclear Medicine Unit, Assiut University Hospitals.
Exclusion Criteria:
Adult patients with histopathologically confirmed differentiated thyroid carcinoma who underwent preoperative fine-needle aspiration cytology and are followed at the Nuclear Medicine Unit, Assiut University Hospitals.
Proportion of patients with high ATA risk stratification
Proportion of patients classified as high risk according to the American Thyroid Association (ATA) risk stratification system.
Time frame: At 1 month
Proportion of patients with papillary thyroid carcinoma subtype
Proportion of patients with papillary thyroid carcinoma histopathological subtype.
Time frame: Baseline
Proportion of patients receiving radioactive iodine therapy
Proportion of patients who received radioactive iodine (RAI) therapy.
Time frame: At 6 months
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University